Trials / Completed
CompletedNCT05331014
To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension
A Multi-center, Randomized, Double-blind, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients With Dyslipidemia and Hypertension.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- JW Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.
Detailed description
Multicenter, randomized, double-blind, parallel-design, phase III clinical study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LivaloVA | For 8 weeks(PO, QD) |
| DRUG | LivaloV | For 8 weeks(PO, QD) |
| DRUG | VA | For 8 weeks(PO, QD) |
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2022-11-08
- Completion
- 2022-11-08
- First posted
- 2022-04-15
- Last updated
- 2024-03-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05331014. Inclusion in this directory is not an endorsement.